Evidence map›Paper›PMID 39737130›Full record

ArticleCytoJournal2024

Targeting the Ajuba/Notch axis increases the sensitivity of colon cancer cells to 5-fluorouracil.

Xinghua Liang, Xuelian Liu, Long Zhang, Junhao Liu, Rong Yan, Haiyan Li, Xiancheng Zeng, Hong Wang

Abstract read
In one paragraph

Article in CytoJournal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xinghua LiangThe First Clinical Medical College, Jinan University, Guangzhou, China.
Xuelian LiuDepartment of Gastroenterology, First Affiliated Hospital of Jinan University, Guangzhou, China.
Long ZhangDepartment of Endoscopy Center, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
Junhao LiuDepartment of General Surgery, Guangdong Second Provincial General Hospital, Guangzhou, China.
Rong YanDepartment of Gastroenterology, The Fourth Affiliated Hospital of Guangzhou Medical University (Zengcheng District People`s Hospital of Guangzhou), Guangzhou, China.
Haiyan LiDepartment of Gastroenterology, The Fourth Affiliated Hospital of Guangzhou Medical University (Zengcheng District People`s Hospital of Guangzhou), Guangzhou, China.
Xiancheng ZengDepartment of General Surgery, Guangdong Second Provincial General Hospital, Guangzhou, China.
Hong WangThe First Clinical Medical College, Jinan University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Colorectal cancer is severely challenging because of the insufficient understanding of the mechanism underlying its resistance to clinical chemotherapy. The purpose of our study is to investigate the role of the LIM protein Ajuba (JUB) in the chemoresistance of colon cancer and its potential effect on clinical treatment. Material and Methods: The protein levels of JUB in colon cancer tissues were evaluated using Western blot analysis and immunohistochemistry assays. The correlation between JUB and the prognosis of patients with colorectal cancer was determined using Kaplan-Meier plot analysis. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays were employed to determine the 50% inhibitory concentration of 5-fluorouracil (5-FU) and thus assess the effect of JUB on the effectiveness of 5-FU. In addition, the rate of cellular apoptosis was measured using fluorescence-activated cell sorting assays. Side population and sphere formation analyses were conducted to determine the role of JUB in promoting the stem cell-like traits of colon cancer cells. Results: JUB expression was upregulated in chemoresistant colon cancer ( Conclusion: Results suggest that JUB plays an important role and may serve as a biomarker for the clinical treatment of patients with 5-FU-resistant colon cancer.

Indexed as

5-fluorouracilAjubaChemoresistanceColon cancerNotch signaling

Identifiers

PMID39737130
PMCPMC11683402

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.